Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune rejuvenation
This is an excellent map of where longevity starts becoming a development discipline and stops being a vibe. Also, excellent emphasis on the bottleneck beneath the therapeutic buckets: biomarkers, endpoints, and indication strategy. Until aging itself has a cleaner regulatory path, the field will keep proving its case indirectly, one proxy disease at a time.
Thanks, you are right. Btw, to your point, here is an earlier article that explores this exact question about how aging research companies workaround the absence of a regulatory path towards aging directly: https://www.techlifesci.com/p/three-big-ideas-in-aging-research
This is an excellent map of where longevity starts becoming a development discipline and stops being a vibe. Also, excellent emphasis on the bottleneck beneath the therapeutic buckets: biomarkers, endpoints, and indication strategy. Until aging itself has a cleaner regulatory path, the field will keep proving its case indirectly, one proxy disease at a time.
Thanks, you are right. Btw, to your point, here is an earlier article that explores this exact question about how aging research companies workaround the absence of a regulatory path towards aging directly: https://www.techlifesci.com/p/three-big-ideas-in-aging-research